These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 30986809)

  • 1. Potential role of cyclin-dependent kinase 4/6 inhibitors in the treatment of squamous cell carcinoma of the head and neck.
    van Caloen G; Machiels JP
    Curr Opin Oncol; 2019 May; 31(3):122-130. PubMed ID: 30986809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Activity of Ribociclib in Squamous Cell Carcinoma of the Head and Neck.
    van Caloen G; Schmitz S; El Baroudi M; Caignet X; Pyr Dit Ruys S; Roger PP; Vertommen D; Machiels JP
    Mol Cancer Ther; 2020 Mar; 19(3):777-789. PubMed ID: 31924739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDK4/6 inhibitors in P16/HPV16-negative squamous cell carcinoma of the head and neck.
    Billard-Sandu C; Tao YG; Sablin MP; Dumitrescu G; Billard D; Deutsch E
    Eur Arch Otorhinolaryngol; 2020 May; 277(5):1273-1280. PubMed ID: 32162057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of CDK4/CDK6 Enhances Radiosensitivity of HPV Negative Head and Neck Squamous Cell Carcinomas.
    Göttgens EL; Bussink J; Leszczynska KB; Peters H; Span PN; Hammond EM
    Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):548-558. PubMed ID: 31271827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial.
    Adkins D; Ley J; Neupane P; Worden F; Sacco AG; Palka K; Grilley-Olson JE; Maggiore R; Salama NN; Trinkaus K; Van Tine BA; Steuer CE; Saba NF; Oppelt P
    Lancet Oncol; 2019 Sep; 20(9):1295-1305. PubMed ID: 31351869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Kinome-Wide Synthetic Lethal CRISPR/Cas9 Screen Reveals That mTOR Inhibition Prevents Adaptive Resistance to CDK4/CDK6 Blockade in HNSCC.
    Goto Y; Koshizuka K; Ando T; Izumi H; Wu X; Sato K; Ishikawa T; Ford K; Feng X; Wang Z; Arang N; Allevato MM; Kishore A; Mali P; Gutkind JS
    Cancer Res Commun; 2024 Jul; 4(7):1850-1862. PubMed ID: 38954773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D
    Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do CDK4/6 inhibitors have potential as targeted therapeutics for squamous cell cancers?
    Kalu NN; Johnson FM
    Expert Opin Investig Drugs; 2017 Feb; 26(2):207-217. PubMed ID: 28042706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer.
    Sobhani N; D'Angelo A; Pittacolo M; Roviello G; Miccoli A; Corona SP; Bernocchi O; Generali D; Otto T
    Cells; 2019 Apr; 8(4):. PubMed ID: 30959874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
    Michel L; Ley J; Wildes TM; Schaffer A; Robinson A; Chun SE; Lee W; Lewis J; Trinkaus K; Adkins D
    Oral Oncol; 2016 Jul; 58():41-8. PubMed ID: 27311401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
    Spring LM; Zangardi ML; Moy B; Bardia A
    Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    Cersosimo RJ
    Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Evaluation of the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor, Ribociclib, and Cetuximab in Squamous Cell Carcinoma of the Head and Neck.
    van Caloen G; Schmitz S; van Marcke C; Caignet X; Mendola A; Pyr Dit Ruys S; Roger PP; Vertommen D; Machiels JP
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33809148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting STAT3 potentiates CDK4/6 inhibitors therapy in head and neck squamous cell carcinoma.
    Dong L; Liu C; Sun H; Wang M; Sun M; Zheng J; Yu X; Shi R; Wang B; Zhou Q; Chen Z; Xing B; Wang Y; Yao X; Mei M; Ren Y; Zhou X
    Cancer Lett; 2024 Jul; 593():216956. PubMed ID: 38735381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.
    Scott SC; Lee SS; Abraham J
    Semin Oncol; 2017 Dec; 44(6):385-394. PubMed ID: 29935900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin D-CDK4/6 functions in cancer.
    Gao X; Leone GW; Wang H
    Adv Cancer Res; 2020; 148():147-169. PubMed ID: 32723562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Laderian B; Fojo T
    Semin Oncol; 2017 Dec; 44(6):395-403. PubMed ID: 29935901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.
    Ku BM; Yi SY; Koh J; Bae YH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Oncotarget; 2016 Mar; 7(12):14803-13. PubMed ID: 26909611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer.
    Fang H; Huang D; Yang F; Guan X
    Breast Cancer Res Treat; 2018 Apr; 168(2):287-297. PubMed ID: 29236235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
    Shah AN; Cristofanilli M
    Curr Treat Options Oncol; 2017 Jan; 18(1):6. PubMed ID: 28197838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.